Capital Analysts LLC’s Matinas BioPharma MTNB Stock Holding History

Capital Analysts LLC’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-25	Closed	-$1K	–	783
2020 Q3	$1K	Hold	25	–	–	﹤0.01%	735
2020 Q2	$1K	Hold	25	–	–	﹤0.01%	685
2020 Q1	$1K	Hold	25	–	–	﹤0.01%	664
2019 Q4	$3K	Buy	+25	New	+$1.45K	﹤0.01%	652
2019 Q3	–	Sell	-25	Closed	-$1K	–	716
2019 Q2	$1K	Hold	25	–	–	﹤0.01%	663
2019 Q1	$1K	Hold	25	–	–	﹤0.01%	634
2018 Q4	$1K	Buy	+25	New	+$981	﹤0.01%	576

Other funds holding MTNB

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Capital Analysts LLC's MTNB Position: Q4 2020 in Review

Capital Analysts LLC sold out of Matinas BioPharma (MTNB) in Q4 2020, closing a stake of 25 shares — an estimated $1K sold.

Capital Analysts LLC first reported a position in MTNB in Q4 2018 and held it in 7 quarters. The position peaked at $3K in Q4 2019. 71 funds tracked by Wall St. Rank hold MTNB as of Q4 2020.

Capital Analysts LLC reported no remaining Matinas BioPharma position as of Q4 2020 after selling out during the quarter.
Capital Analysts LLC sold 25 Matinas BioPharma shares in Q4 2020, an estimated $1K.
Capital Analysts LLC first reported a position in Matinas BioPharma in Q4 2018 and held it in 7 quarters.
Capital Analysts LLC's Matinas BioPharma position peaked at $3K in Q4 2019.
71 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2020.

Based on Capital Analysts LLC's 13F filing for Q4 2020, filed 16 Feb 2021.